In the face of market and individual stock fluctuations, more and more A-share listed companies have joined the repurchase army. According to Oriental wealth statistics, since 2022, about 200 listed companies have launched repurchase plans. In February, 109 listed companies issued repurchase plans or announced progress, mostly in electronics, medicine, medical equipment, chemical and other industries. Among them, Hengli Petrochemical has invested about 500 million yuan to implement, and the upper limit of Maiwei share repurchase is as high as 650 yuan / share. In November 2021, Hengli Petrochemical plans to use its own funds or self raised funds to repurchase the company's shares through centralized bidding in the next 12 months, and the total scale of repurchase funds will be between 500 million yuan and 1 billion yuan; The repurchase price shall not exceed 35 yuan / share. As of February 14, the company has implemented the first repurchase, involving 19.2896 million shares, accounting for 0.27% of the total share capital of the company. The transaction price ranges from 24.8 yuan / share to 26.51 yuan / share, and the total amount paid is about 500 million yuan. In the first three quarters of last year, Hengli Petrochemical achieved a net profit of about 12.7 billion yuan, a year-on-year increase of 28.46%. Among them, the company's profit growth rate decreased in the third quarter, and the net profit decreased by about 10% month on month. At the same time, the company continues to expand its production. In January this year, Hengli Petrochemical disclosed that it will invest 1.6 million tons / year of high-performance resin and new materials. It is expected that the total investment will be about 20 billion yuan to speed up the layout of electronic grade new materials. In addition, the company will invest 4 billion yuan in the high-performance polyester project with an annual output of 2.6 million tons. From the perspective of market performance, the share price of Hengli Petrochemical hit a high of 49.03 yuan / share in February last year, and then the share price continued to decline, with a cumulative decline of more than 50%; Since the company launched the repurchase plan, the share price rebounded and rose 17.63%, and the latest closing was 25.16 yuan / share. As the leading target of fingerprint identification chip, the share price of huiding shares continued to decline after reaching a high of 386.75 yuan / share on February 26, 2020. The latest closing market value was reduced to 41.5 billion yuan and the closing price was 90.75 yuan / share. Since the first quarter of 2020, the company's profit growth has continued to decline; In the third quarter of last year, the company's net profit fell by about 60%. On February 12, huiding technology disclosed the repurchase plan, which plans to repurchase the shares issued by the company with its own funds of 400 million to 500 million yuan, all of which are used to implement the company's employee stock ownership plan. The repurchase price is no more than 126 yuan / share (inclusive), and the repurchase period is no more than 12 months from the date when the board of directors deliberates and approves the share repurchase plan, that is, from February 11, 2022 to February 10, 2023. On the evening of February 14, huiding technology released the repurchase report again. According to the upper limit, the number of shares repurchased is expected to be about 3.9683 million, accounting for about 0.87% of the total share capital of the company; According to the lower limit, the number of shares repurchased is expected to account for 0.69% of the total share capital of the company. Hang Seng electronics also disclosed on the evening of February 14 that it plans to repurchase shares with 100 million yuan to 150 million yuan, with a repurchase price of no more than 80 yuan / share. The repurchased shares are used for equity incentive or employee stock ownership plan. On the same day, Maiwei's share disclosure plan repurchased shares with 163 million yuan to 325 million yuan, with the upper limit of repurchase price not exceeding 650 yuan / share, ranking first among the listed companies that have disclosed the repurchase plan. The shares repurchased by the company will also be used for equity incentive or employee stock ownership plan. Calculated according to the upper and lower limits of repurchased shares, it accounts for about 0.23% ~ 0.46% of the issued share capital of the company. The performance forecast shows that Maiwei shares is expected to achieve a profit of 580 million yuan to 680 million yuan last year, an increase of 47.05% ~ 72.4% over the same period last year; The net profit after deducting non profits increased by 59.54% ~ 89.08% over the same period of last year. The sales volume of the company's main product solar cell screen printing equipment has increased steadily, which makes the company's net profit maintain a high growth rate. However, in terms of market performance, Maiwei's share price has fallen by nearly 40% since mid December last year. Ed biology also launched a repurchase plan, which plans to spend 100 million yuan to 200 million yuan to repurchase shares at a price of no more than 95 yuan / share. The repurchased shares will be used for equity incentive or employee stock ownership plan. Based on the upper and lower limits of the total amount of funds repurchased this time, the shares repurchased this time account for about 0.47% to 0.95%. In the first three quarters of last year, the operating cost of aide biology increased by 70% year-on-year, far exceeding the growth rate of revenue. The net profit reached 177 million yuan, an increase of about 40% year-on-year. Among them, the net profit in the third quarter decreased by nearly 4% month on month. The company pointed out that the revenue growth was mainly due to the increase in the sales of polygenic combined reagent products, and the cost of polygenic combined reagent was high; The cost of testing service increases, while the cost of product cold chain transportation increases. Since the release of the third quarterly report, the company's share price has continued to decline since late December last year, with a cumulative decline of more than 36%. (Xinhua News Agency)